Tian Zhi, Jia Wei, Wang Zhao, Mao Hui, Zhang Jingjing, Shi Qiongya, Li Xing, Song Shaoyu, Zhang Jiao, Zhu Yingjie, Yang Bo, Huang Chunhai, Huang Jun
Department of Neurosurgery, First Affiliated Hospital, Jishou University, Jishou, Hunan, 416000 PR China.
Medical College of Jishou University, Jishou, Hunan, 416000 PR China.
Heliyon. 2024 Apr 9;10(8):e29275. doi: 10.1016/j.heliyon.2024.e29275. eCollection 2024 Apr 30.
The clinical significance of immune-related antigen in gliomas remains uncertain. The aim of this study was to examine the clinical importance and possible core related genes of CD58 in gliomas.
Pan-cancer analysis was to observe the association between and different tumors, glioma RNA sequencing data and clinical sample analyses were used to observe the relationship between and glioma, shRNA interference models were to observe the impact of on glioma cell function, and four glioma datasets and two online analysis platforms were used to explore the core related genes affecting the correlation between and glioma.
High expression was associated with worse prognosis in various tumors and higher malignancy in glioma. Down regulation of CD58 expression was linked to decreased proliferation, increased apoptosis, and reduced metastasis in glioma cells. The pathways involved in -related effects were enriched for immune cell adhesion and immune factor activation, and the core genes were and . The signature of and its core-related genes showed superior predictive power for glioma prognosis.
High expression is correlated with more malignant glioma types, and also an independent risk factor for mortality in glioma. and its core-related genes may serve as novel biomarkers for diagnosing and treating glioma.
胶质瘤中免疫相关抗原的临床意义仍不确定。本研究的目的是探讨CD58在胶质瘤中的临床重要性及可能的核心相关基因。
泛癌分析用于观察其与不同肿瘤的关联,胶质瘤RNA测序数据及临床样本分析用于观察其与胶质瘤的关系,shRNA干扰模型用于观察其对胶质瘤细胞功能的影响,四个胶质瘤数据集和两个在线分析平台用于探索影响其与胶质瘤相关性的核心相关基因。
高表达与多种肿瘤的预后较差及胶质瘤的更高恶性程度相关。CD58表达下调与胶质瘤细胞增殖减少、凋亡增加及转移减少有关。与CD58相关效应所涉及的通路在免疫细胞黏附和免疫因子激活方面富集,核心基因是[具体基因1]和[具体基因2]。CD58及其核心相关基因的特征对胶质瘤预后显示出卓越的预测能力。
高CD58表达与更恶性的胶质瘤类型相关,也是胶质瘤患者死亡的独立危险因素。CD58及其核心相关基因可能作为诊断和治疗胶质瘤的新型生物标志物。